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PNGase F (N-glycanase) was obtained from the Complex Carbohydrate Research Center, 
University of Georgia, (Dr. Kelley Moremen). PNGase A was acquired from NEB. N-Glycan 
standards were obtained from the Consortium for Functional Glycomics (CFG) and from The 
Scripps Research Institute (Dr. James Paulson). O-Glycan standards were obtained as part of an 
NIH Common Fund grant (R21AI123161) from the University of Georgia (Dr. Christopher M. 
West). Sodium hydroxide (50%) was purchased from Fisher Scientific. Sep-Pak C18 disposable 
extraction columns were obtained from Waters Corporation (Milford, MA, USA). AG-50W-X8 
cation exchange resin (H+ form) was purchased from Bio-Rad and trifluoroacetic acid from Pierce. 
Malto-series oligosaccharides were obtained from Wako Chemicals (Richmond, VA). Trypsin, 
Chymotrypsin, bovine pancreatic ribonuclease B (RNaseB), Fetuin, Dextran (Leuconostoc spp., 
Cat# 31388) and all other chemical reagents were purchased from Sigma-Aldrich (St. Louis, MO, 
USA).  Fly powder, a dried preparation of Drosophila embryo glycoproteins, was prepared as 
previously described and used as a source of pauci-mannose glycans (11). Mouse brain extracts 
were prepared as previously described for analysis of brain O-glycans (12).  HIV gp120 was 
recombinantly expressed in glyco-engineered Pichia pastoris strains obtained from GlycoFi 
(Lebanon, NH) in order to generate proteins with restricted glycan diversity (13, 14).    
Primary mouse tracheal epithelial cells (mTEC), mouse brain (Pel-Freez Biologicals), or HEK293 
cells (kind gift from Dr. Henrik Clausen, University of Copenhagen, Denmark) were homogenized 
in ice-cold 50% (v/v) aqueous methanol and delipidated with chloroform/methanol/water (4:8:3, 
v/v/v) as described previously (11, 15). Insoluble proteins were precipitated by centrifugation and 
protein pellets were washed twice with ice-cold acetone prior to drying under a gentle Nitrogen 
stream to produce fine protein powder. 2-3 mg of protein powder were then subjected to reductive 
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β-elimination and the released O-glycan alditols purified as described previously (16). Briefly, 
protein powder was resuspended in 100 mM NaOH containing 1 M NaBH4 and incubated for 18 
h at 45°C in a glass tube sealed with a Teflon-lined screw top. After incubation, the reaction 
mixture was neutralized with 10% acetic acid on ice and desalted using a AG-50W-X8 (H+ form) 
column (1 mL bed volume) prior to borate removal and Sep-pack C18 cartridge clean-up.  
Preparation of glycopeptides and release of N-glycans was performed as described previously 
(11). Briefly, 20-75 μg of glycoproteins (RNAse B, Fetuin, gp120) were dried and resuspended in 
trypsin buffer (0.1 M Tris-HCl, pH 8.2, containing 1 mM CaCl2) by sonication and boiled for 5 min 
before addition of trypsin and chymotrypsin solutions. After incubation for 18 h at 37 °C, the 
(glyco)peptide mixture was boiled for 5 min and adjusted to 5% AcOH (acetic acid) prior to a Sep-
Pak C18 cartridge column clean up. Glycopeptides were eluted stepwise in 20% isopropyl alcohol 
in 5% acetic acid and 40% isopropyl alcohol in 5% acetic acid. Both, the 20 and 40% isopropyl 
alcohol fractions were pooled and evaporated to dryness. Dried glycopeptides were resuspended 
in 25 mM sodium phosphate buffer, pH 7.5, for digestion with PNGaseF (fetuin, ribonuclease B) 
or in 50 mM ammonium acetate buffer, pH 4.5, for digestion with PNGaseA (fly powder) prior to 
incubation for 18 h at 37 °C. PNGase-released oligosaccharides were separated from residual 
(glyco)peptides by another round of Sep-Pak C18 cartridge clean-up.  
For the reduction of PNGase-released N-glycans and standards, dried glycans were resuspended 
in 100 μL of 50 mM NaOH, vortexed and ultrasonic water bath sonicated prior to the addition of 
100 μL 2% (w/v) NaBH4 in 50 mM NaOH. After incubation for at least 4 hours at RT, 200 μL of 
10% (v/v) AcOH were added to neutralize the reaction. Samples were dried down under a gentle 
Nitrogen stream prior to borate removal by adding 400 μL of 10% (v/v) AcOH in methanol and 
repeated evaporation (up to 3 times).  
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N-glycans O-glycans
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Figure 1. General workflow for preparation of N- and O-glycans. 
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FIGURE 2 - Mobile Phase Optimization

























A: 0.1% Formic Acid in water
RT:0.00 - 180.01









































EIC: 512.3 (H+), 518.3 (Li+), 534.3 (Na+),  550.3 (K+)
NL: 6.61E5
EIC: 757.4 (H+), 763.5 (Li+), 779.4 (Na+), 795.4 (K+) 
NL: 2.33E5
EIC: 961.5 (H+), 967.6 (Li+), 983.5 (Na+), 999.5 (K+)
NL: 1.70E6
EIC: 873.5 (H+), 879.5 (Li+), 895.5 (Na+), 911.4 (K+)
NL: 7.60E5
EIC: 617.8 (H2+), 623.8 (Li2+), 639.8 (Na2+), 655.8 (K2+),
 1234.7 (H+), 1240.7 (Li+), 1256.6 (Na+), 1272.6 (K+)       
NL: 1.52E6
NL: 4.17E5
EIC: 661.9 (H2+), 667.9 (Li2+), 683.8 (Na2+), 699.8 (K2+),
 1322.7 (H+), 1328.7 (Li+), 1344.7 (Na+), 1360.6 (K+)       
EIC: 711.7 (H3+), 717.7 (Li3+), 733.7 (Na3+), 749.7 (K3+),
 1067.1 (H2+), 1073.1 (Li2+), 1089.0 (Na2+), 1105.0 (K2+)       
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A: 0.1% Formic Acid in water
B: 0.1% Formic Acid in 80% ACN
A: 0.1% Acetic Acid, 0.1 mM LiOAc in water
B: 0.1% Acetic Acid, 0.1 mM LiOAc in 80% ACN
A: 0.02% Acetic Acid, 1 mM LiOAc in water
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Figure 2. Addition of lithium acetate to LC-mobile phases enhances ionization. Reduced O-glycans from mouse trachea 
-
A) LC-chromato-
B) demonstrating baseline separation of permethylated O-glycans separated in 
common proteomics buffers (Formic acid/Acetonitrile). (C) Observed alkali metal adduct ions for the three mobile phase condi-
tions tested demonstrated optimal ionization and adduct formation in 0.02% Acetic Acid containing 1 mM lithium acetate. (D) 
MS/MS fragmentation of two glycan isoforms are shown.
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B: 0.02% Acetic Acid, 1 mM LiOAc in 80% ACN
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B: 0.02% Acetic Acid, 1 mM LiOAc in 80% ACN
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FIGURE 3 - Gradient  Optimization
Figure 3. LC-gradient optimization for reduced N-glycans. Initial separation of paucimannose, high-mannose and complex type N-glycans was 
achieved with a gradient from 30-70% B (A), but separation of larger N-glycans (e.g. tetra-antennary) might be insufficient. (B) Rapid increase in the gradi-
ent to 45% B in 5 min followed by a shallow gradient from 45-70% B seems to be more suitable for larger N-glycans (e.g. tri/tetra-antennary). Attempts to 
shorten the gradient program to less than 180 min using steeper gradients resulted in suboptimal separation of glycans and co-eluting species (data not 
shown).
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Figure 4. Elution of permethylated glycans expressed in terms of Glucose Units. (A) Reduced and 13C-per-
methylated Dextran (isomaltooligosaccharide series, DP4 to 10) was separated using a PepMap Acclaim C18 
column in 1 mM lithium acetate-containing mobile phases (45-70% B over 150 mins). Extracted ion chromatogram 
for each predicted mass is shown (within 10 ppm). Retention times of DP standards, run both before and after sample 
acquisition queue, were averaged and plotted using a linear regression fitting. Error bars represent standard devia-
tion (See inset). (B) Reduced and 13C-permethylated CFG N-Glycan standards (107-110, 121) were analyzed as 
described in Panel A. (C) Summary table of analyzed CFG standards with retention times converted to reversed 
phase glucose units (RP g.u.; using linear regression fitting shown in Panel A, inset).
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EIC m/z 932.5 [M+Li]+
FIGURE 5 - O-Glycan Isomeric Standards





Identification Composition [M+Li]+ RP g.u. Structure
TET-023 Galp 1,2Galp 1,6(U-13C-Galp 1,4)GlcNAcitol 932.5 2.88
TET-024 Galp 1,2Galp 1,6(U-13C-Galp 1,3)GlcNAcitol 932.5 2.86
TET-025 Galp 1,2Galp 1,6(U-13C-Galf 1,4)GlcNAcitol 932.5 3.22
TET-026 Galp 1,3Galp 1,6(U-13C-Galf 1,4)GlcNAcitol 932.5 3.26
Figure 5. LC-NSI-MS of Permethylated Isomers. 
Extracted ion chromatograms showing individual (A-D) or 
a mixture (E) of four tetrasaccharide O-glycan isomers 
that only differ by the cyclic form of a single sugar [pyra-
nose (p) or furanose (f)] or a single linkage (differences 
indicated in green). Separation was performed using a 
PepMap Acclaim C18 column in 1 mM lithium 
acetate-containing mobile phases with a modified gradi-
ent (35-40% B over 170 mins) and detected using a 
Thermo Velos Pro ITMS. (F) Summary table of isomers 
used with retention times converted to reversed phase 
glucose units (RP g.u.; referenced to 13C-permethylated 
isomaltooligosaccharide standards separated using the 
same gradient).
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Figure 6. LC-NSI-MSn analysis of N-glycans released from recombinant gp120 expressed in 
cell lines defective in N-glycosylation machinery. (A) Extracted ion chromatograms of all predict-
ed PNGaseF-released, reduced, and permethylated N-glycans from various gp120 expressing cell 
lines, either individual (A-F) or as a mixture (G). (H) Automated, intelligent MSn fragmentation defines 
sialic acid linkage position in realtime from Structure #10. (I) Summary table of gp120 N-glycans with 
retention times converted to reversed phase glucose units (RP g.u.; referenced to 13C-permethylated 
isomaltooligosaccharide standards separated using the same gradient).
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HEK293-WT RT: 26.06 AV: 1 NL: 6.63E5
T: ITMS + c NSI d Full ms2 593.43@cid42.00
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Figure 7. Analysis of reduced and permethylated O-glycans released from mouse brain proteins and cell 
lines defective in O-mannosylation pathway machinery. (A
B
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